<DOC>
	<DOCNO>NCT02257918</DOCNO>
	<brief_summary>This multi-center Phase 2 randomize , open-label study approximately 180 adult male female subject , age 18 55 , good health meet eligibility criterion . The study design assess safety efficacy antimicrobial investigational product , AZD0914 manufacture AstraZeneca , administer adult treat uncomplicated urogenital gonorrhea compare treatment ceftriaxone . Subjects randomly assign 70:70:40 receive single , oral dose 2000 mg AZD0914 , 3000 mg AZD0914 , intramuscular dose 500 mg ceftriaxone . The drug name also know ETX0914 .</brief_summary>
	<brief_title>Randomized , Open-label Phase 2 Study Oral AZD0914 Treatment Gonorrhea</brief_title>
	<detailed_description>Uncomplicated gonorrhea currently second common bacterial sexually transmit infection ( STI ) worldwide , accordingly , serious public health problem . This multi-center Phase 2 randomize , open-label study approximately 180 adult male female subject , age 18 55 , uncomplicated cervical urethral gonorrhea . The study design assess safety efficacy antimicrobial investigational product , AZD0914 manufacture AstraZeneca , administer adult treat uncomplicated urogenital gonorrhea compare treatment intramuscular ceftriaxone . Subjects randomly assign 70:70:40 receive single , oral dose 2000 mg AZD0914 , 3000 mg AZD0914 , intramuscular dose 500 mg ceftriaxone . The study duration 11 month subject participation 30 day . Subjects 1 ) untreated urethral cervical gonorrhea identify via laboratory test prior visit , 2 ) untreated subject acknowledge anal , oral , vaginal sexual contact past 14 day someone diagnose gonorrhea , 3 ) sign symptoms urethral cervical gonorrhea offer enrollment study consent . The primary objective ass efficacy microbiological cure rate 2000 mg 3000 mg AZD0914 compare 500 mg ceftriaxone treatment uncomplicated urogenital gonorrhea . The second primary objective ass safety tolerability single oral dose 200 mg 3000 mg AZD0914 compare 500 mg ceftriaxone adult subject uncomplicated urogenital gonorrhea . The drug name also know ETX0914 .</detailed_description>
	<mesh_term>Gonorrhea</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<criteria>1 . Untreated subject sign symptom urethral cervical gonorrhea , confirm urethral cervical gonorrhea* type sexual contact past 14 day infect individual . *As define positive culture , NAAT test , Gramstain 2 . Subject able give voluntary write informed consent study related procedure perform 3 . Willingness comply protocol requirement 4 . Male nonpregnant female 18 55 year age , inclusive 5 . If subject female , negative urine pregnancy test Visit 1 prior receive study drug 6 . Subject willing abstain anal , oral , vaginal sexual intercourse use condom 7 day follow study drug dose prevent potential gonococcal reinfection 7 . Male subject must surgically sterilize use condom 7 day follow study drug dose 8 . Female subject must nonchildbearing potential* childbearing potential , must use highly effective method birth control** *Nonchildbearing potential define postmenopausal least two year , status bilateral oophorectomy status hysterectomy . **Female subject must avoid become pregnant use one follow acceptable method birth control 30 day prior study drug dosing : Intrauterine contraceptive device ; OR Oral contraceptive ; OR Implanon速 , Nexplanon速 , DepoProvera速 , contraceptive skin patch NuvaRing速 , OR Tubal ligation OR Abstinence AND 30 day follow dosing , method use plus require use barrier method ( condom ) male partner ( even vasectomize ) 1 . Confirmed suspect , complicate systemic gonorrhea pelvic inflammatory disease , testicular pain , epididymitis , arthritis , conjunctivitis endocarditis clinical proctitis . 2 . Known concomitant infection would require immediate additional systemic antibiotic 3 . Female subject currently breastfeed 4 . Use systemic intravaginal antibiotic activity N. gonorrhoeae systemic antiviral within 30 day prior study drug administration ( topical intravaginal antifugals permit ) . 5 . Use systemic corticosteroid drug immunosuppressive therapy within 30 day prior enrollment 6 . Cytotoxic chemotherapy radiation therapy within previous 3 month 7 . Known chronic renal , hepatic ( include chronic hepatitis B hepatitis C infection ) hematologic impairment , condition could interfere absorption metabolism study drug 8 . Any concomitant condition , opinion Investigator , would preclude evaluation response make unlikely course therapy followup could complete 9 . Subject HIVinfected take antiretroviral medication Subject HIVinfected take antiretroviral pre post exposure prophylaxis Subject newly diagnose HIV infection know HIV infect evidence immunosuppression , document patient report CD4 count &lt; 200 10 . Known allergy cephalosporin penicillin antibiotic 11 . Receipt plan receipt investigational product clinical trial within 30 day prior 7 day study dose administration 12 . Female subject willing defer treatment bacterial vaginosis Visit 2 test positive bacterial vaginosis Visit 1 . 13 . Use drug act inducer/inhibitors CYP3A4/5 Pgp efflux transporter* within 30 day prior study drug administration *such itraconozale , fluconazole , ketoconazole , verapamil , diltiazem , amiodarone , felodipine , carbamazepine , phenytoin , St. John 's wort 14 . Subjects know coinfected chlamydia prior study entry 15 . Subjects medically document cardiac arrhythmia 16 . Known allergy lidocaine ( local anesthetic amide type , e.g. , articaine , bupivacaine , mepivacaine , prilocaine , ropivacaine ) antimicrobial preservative methylparaben .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 5, 2016</verification_date>
	<keyword>antibiotic</keyword>
	<keyword>antimicrobial</keyword>
	<keyword>AZD0914</keyword>
	<keyword>Ceftriaxone</keyword>
	<keyword>drug-resistant</keyword>
	<keyword>sexually transmit infection</keyword>
	<keyword>urogenital gonorrhoea</keyword>
</DOC>